EU gives green light to Kimberly-Clark's (Kleenex) acquisition of Kenvue (Neutrogena)
Article excerpt
Highlighted: the sentence this signal was extracted from
The European Union announced on Tuesday that it has given the green light to the $48.7 billion acquisition of American consumer goods giant Kimberly-Clark by health company Kenvue, while ensuring that feminine hygiene products remain "affordable". (illustration) ( GETTY IMAGES NORTH AMERICA / MONICA SCHIPPER ) Based in Texas, Kimberly-Clark manufactures a wide range of paper and textile-based products, with brands like Huggies, Kleenex, and Kotex. Kenvue, for its part, manages consumer health brands ranging from Neutrogena and Listerine to Tylenol pain relievers and Nicorette. The European Commission, the EU's competition regulator, concluded that the acquisition would reduce competition in the tampon supply markets, particularly in the Czech Republic, Estonia, and Slovakia. Kimberly-Clark has proposed divesting all of its tampon brands and other feminine hygiene products sold in the European Economic Area, which includes the 27 EU countries as well as Iceland, Liechtenstein, and Norway. The brands concerned are Kotex, including the sub-brand Lidie, as well as Camelia and Record, the Commission stated in a press release. The EU announced that it has approved the acquisition of these brands by the Turkish company Dilek. "Kimberly-Clark's commitment to divest its feminine hygiene brands, including Kotex, Camelia, and Record, will preserve competition, choice, and affordable...
Keep reading with a free account
The rest of this article, and every signal for Kenvue, is in your free account.
